Safety study comparing two diabetes medicines for cancer risk

This is a large, long-term safety study comparing exenatide with other diabetes medications used by type 2 diabetes patients across seven European countries. Researchers will examine medical records and prescription data collected between 2006 and 2023 to understand whether people taking exenatide have different rates of pancreatic cancer compared to those taking other diabetes medications. The study involves 24,000 patients and uses existing health records—no new medical visits or tests are needed from participants.

Some diabetes medications have raised safety questions over the years. This study exists to carefully examine whether this medication is associated with any increased risk of pancreatic cancer, which helps ensure that doctors and patients have trustworthy information to make informed treatment decisions.